Olema Pharmaceuticals
Olema Pharmaceuticals
OLMA
NASDAQ
11.80
USD
103.80%
About
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD).
The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis.
It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 560.1K |
| Three Month Average Volume | 18.8M |
| High Low | |
| Fifty-Two Week High | 17.7911 USD |
| Fifty-Two Week Low | 8.51 USD |
| Fifty-Two Week High Date | 08 Nov 2023 |
| Fifty-Two Week Low Date | 24 May 2024 |
| Price and Volume | |
| Current Price | 11.8 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -20.90% |
| Thirteen Week Relative Price Change | 13.90% |
| Twenty-Six Week Relative Price Change | -27.49% |
| Fifty-Two Week Relative Price Change | -7.22% |
| Year-to-Date Relative Price Change | -28.98% |
| Price Change | |
| One Day Price Change | 2.16% |
| Thirteen Week Price Change | 21.90% |
| Twenty-Six Week Price Change | -20.27% |
| Five Day Price Change | -1.26% |
| Fifty-Two Week Price Change | 16.26% |
| Year-to-Date Price Change | -15.89% |
| Month-to-Date Price Change | -26.98% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.61688 USD |
| Book Value Per Share (Most Recent Quarter) | 3.96733 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 4.61688 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.96733 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.28998 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.13616 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.06201 USD |
| Normalized (Last Fiscal Year) | -2.13616 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.13616 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.06201 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.13616 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.06201 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.76075 USD |
| Cash Per Share (Most Recent Quarter) | 4.17588 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.12783 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.06335 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.74542 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 125.21% |
| Tangible Book Value (5 Year) | 141.83% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -9.39% |
| EPS Change (Trailing Twelve Months) | 14.56% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -239,104,000 |
| Net Debt (Last Fiscal Year) | -261,807,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 12 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -83,727,000 |
| Free Cash Flow (Trailing Twelve Months) | -92,430,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -39.24% |
| Return on Assets (Trailing Twelve Months) | -50.73% |
| Return on Assets (5 Year) | -30.06% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -42.82% |
| Return on Equity (Trailing Twelve Months) | -56.40% |
| Return on Equity (5 Year) | -32.23% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -42.54% |
| Return on Investment (Trailing Twelve Months) | -56.10% |
| Return on Investment (5 Year) | -31.40% |